Syncona Limited Virginia Holmes Appointed Non-Executive Director (2488J)

TIDMSYNC

RNS Number : 2488J

Syncona Limited

21 December 2020

Syncona Limited

Virginia Holmes Appointed as Non-Executive Director

21 December 2020

Syncona Ltd, a leading healthcare company focused on founding, building and funding a portfolio of global leaders in life sciences, announces the appointment of Virginia Holmes as a Non-Executive Director with effect from 1 January 2021.

Virginia has extensive knowledge of the financial services industry including investment management and banking. She was previously Chief Executive of AXA Investment Managers UK and held a number of senior leadership roles over more than a decade at Barclays Bank Group.

Virginia also brings a wide range of Board experience, both with UK listed companies and organisations across various jurisdictions. She is currently a Non-Executive Director of Intermediate Capital Group plc, a FTSE 100 specialist asset manager, and of the European Opportunities Trust plc, a closed ended European equity fund. She is also Chair of USS Investment Management Ltd, the fiduciary manager of Universities Superannuation Scheme Ltd.

Melanie Gee, Chair of Syncona Limited, said: "We are pleased to strengthen our Board of Directors with the appointment of Virginia. She has extensive experience and a proven track record of working with investment businesses as they look to develop and expand. Her expertise will be invaluable as we look to manage and grow a sustainable portfolio of leading life science companies ."

Virginia Holmes said: "I am very much looking forward to joining Syncona's Board and working with their expert life science investment team, to support them in accelerating the growth of the business and delivering the purpose to invest to extend and enhance human life."

No further details are required to be disclosed under LR 9.6.13.

[ENDS]

Enquiries

Syncona Ltd

Annabel Clay

Tel : [phone]

FTI Consulting

Ben Atwell / Natalie Garland-Collins / Tim Stamper

Tel: [phone]

About Syncona

Syncona (LON: SYNC) is a healthcare company focused on founding, building and funding a portfolio of global leaders in life science. Our purpose is to invest to extend and enhance human life. We do this by founding and building companies to deliver transformational treatments to patients in areas of high unmet need.

Our strategy is to found, build and fund companies around exceptional science to create a dynamic portfolio of 15-20 globally leading healthcare businesses for the benefit of all our stakeholders. We focus on developing treatments for patients by working in close partnership with world-class academic founders and management teams. Our strategic balance sheet underpins our strategy enabling us to take a long-term view as we look to improve the lives of patients with no or few treatment options, build sustainable life science companies and deliver strong risk-adjusted returns to shareholders.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOAFEAFISESSESE

(END) Dow Jones Newswires

December 21, 2020 02:00 ET (07:00 GMT)